PatientsVille.com Logo


Zyloprim Medical Research Studies

Up-to-date List of Zyloprim Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Zyloprim Medical Research Studies

Rank Status Study
1 Recruiting A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
Condition: Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Allopurinol
Outcome Measures: Absolute neutrophil count;   Feasibility of the addition of allopurinol to ALL maintenance therapy;   Safety of the addition of allopurinol to ALL maintenance therapy;   Effects of allopurinol on liver function tests;   Alteration of 6-MP metabolism through the addition of allopurinol
2 Unknown  A Pilot Study for Pharmacokinetic/Pharmacodynamic (PK/PD) Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient
Condition: Chronic Kidney Disease
Outcome Measure:
3 Recruiting Allopurinol in Acute Coronary Syndrome
Condition: Chronic Stable Angina
Interventions: Drug: Allopurinol;   Drug: Placebo
Outcome Measures: Change in time to exercise induced ST depression;   change in total exercise time on Exercise Tolerance Testing (ETT);   Change in time to subjects reported symptoms of chest pain during exercise testing.;   changes in blood markers, specifically Brain Naturetic Peptide (BNP), high sensitivity Troponin T and high sensitivity C Reactive Protein (hsCRP), during exercise testing;   angina pain and Glyceryl TriNitrate (GTN) usage
4 Recruiting Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities
Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat;   Drug: Allopurinol
Outcome Measures: First occurrence of any event in the predefined Major Adverse Cardiovascular Events Composite.;   First occurrence of any Antiplatelet Trialists' Collaborative Event.;   First occurrence of Cardiovascular Death death.;   First occurrence of Non-fatal Myocardial Infarction.;   First occurrence of Non-fatal stroke.;   First occurrence of Unstable Angina with Urgent Coronary Revascularization.
5 Recruiting A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Conditions: Diabetic Nephropathies;   Coronary Artery Disease
Interventions: Drug: Allopurinol;   Drug: Placebo
Outcome Measures: iGFR at the end of the wash-out period;   iGFR at 4 months of treatment;   iGFR the end of treatment period;   iGFR time trajectory;   eGFR time trajectory;   Time to serum creatinine doubling or end stage renal disease (ESRD);   AER at the end of the wash-out period;   AER at the end of the treatment period;   Time to fatal or non-fatal cardiovascular events
6 Recruiting Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   de Novo Myelodysplastic Syndromes;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: rasburicase;   Drug: allopurinol
Outcome Measures: Probability of obtaining a uric acid level =< 7.5mg/dL;   Rate of patients that maintain a uric acid level =< 7.5mg/dL;   Rate of patients requiring additional doses of rasburicase to maintain a uric acid level =< 7.5mg/dL;   Comparison of rate of patients able to maintain a uric acid level =< 7.5mg/dL between the two treatment arms;   Identification and comparison of differential characteristics of patients unable to achieve and/or maintain a uric acid level =< 7.5mg/dL
7 Recruiting Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.
Condition: Patients With Grade II Ankle Sprain
Interventions: Drug: Allopurinol;   Drug: Placebo
Outcome Measures: Muscle mass loss;   The role of xanthine oxidase in the loss of muscle mass;   size of the leg muscles in a group of immobilized subjects.;   oxidative stress parameters
8 Not yet recruiting The Role of Allopurinol in Improving Muscle Energetics in Sarcopenia
Condition: Sarcopenia
Interventions: Drug: Allopurinol;   Drug: Lactose tablets
Outcome Measure: Improvement in Muscle energetics as measured by MR-spectroscopy
9 Unknown  Antenatal Allopurinol in Intrauterine Growth Restriction
Condition: Fetal Growth Retardation
Intervention: Drug: Allopurinol
Outcome Measures: free radical production / oxidative stress;   foetal parameters (Doppler, cardiotocography);   postponement of birth;   morbidity (including long term neurodevelopmental outcome);   mortality;   pharmacokinetices
10 Recruiting Uric Acid and the Endothelium is CKD
Condition: Kidney Disease
Interventions: Drug: Allopurinol;   Other: Placebo
Outcome Measures: Endothelial Dependent Dilation;   Systemic inflammation and oxidative stress;   Inflammation and oxidative stress in the endothelial cells
11 Recruiting Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Condition: Gout
Interventions: Drug: Arhalofenate 600 mg;   Drug: Allopurinol 300 mg;   Drug: Colchicine 0.6 mg;   Drug: Placebo;   Drug: Arhalofenate 800 mg
Outcome Measures: The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group.;   Percent sUA reduction from baseline to Week 12 in the arhalofenate 800 mg group compared to the placebo group;   Percent sUA reduction from baseline to Week 12 in the arhalofenate 600 mg group compared to the placebo group;   Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 800 mg group compared to the placebo group;   The incidence of flares from baseline through Week 12 in the arhalofenate 600 mg group compared to the allopurinol 300 mg group;   Proportion of patients with sUA < 6 mg/dL at Week 12 in the arhalofenate 600 mg group compared to placebo group;   Time from baseline to onset of first flare for the arhalofenate 800 mg group compared to the allopurinol 300 mg group;   Time from baseline to onset of first flare for the arhalofenate 600 mg group compared to the allopurinol 300 mg group
12 Unknown  Intravenous Allopurinol in Heart Failure
Condition: Congestive Heart Failure
Intervention: Drug: allopurinol 300mg intravenous
Outcome Measures: Myocardial CK flux;   Cardiac PCr/ATP
13 Recruiting Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rasburicase;   Drug: Allopurinol
Outcome Measure: Incidence of Laboratory Tumor Lysis Syndrome (LTLS) during cycle-2
14 Recruiting Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Condition: Gout and Hyperuricemia
Interventions: Drug: RDEA3170;   Drug: Allopurinol;   Drug: Placebo
Outcome Measures: Percent changes of serum uric acid levels from baseline levels;   Proportion of subjects with a serum uric acid level ≤6.0 mg/dL;   Serum uric acid levels;   Absolute change of serum uric acid levels from baseline levels;   Percent change of serum uric acid levels from baseline;   Adverse Events, laboratory tests, vital signs, electrocardiograms, gout flare and pain assessment
15 Recruiting Effect of Allopurinol Treatment on Insulin Resistance
Conditions: Hyperuricemia;   Prediabetes;   Insulin Resistance
Interventions: Drug: allopurinol 300 mg./day;   Other: No intervention;   Drug: Normouricemic
Outcome Measure: Change in insulin resistance (HOMA-IR)
16 Recruiting Prednisone for Heart Failure Patients With Hyperuricemia
Condition: Heart Failure, Hyperuricemia
Interventions: Drug: Prednisone;   Drug: Allopurinol
Outcome Measures: Change form baseline in serum creatinine levels;   Change from baseline in uric acid levels;   Change from baseline in Cystatin C;   the levels of tumor necrosis factor (TNF) alfa, interleukin (IL)-1 beta and IL-6 in the circulation;   The levels of angiotensin II and aldosterone in the circulation.;   Daily urine output;   New York Heart Association (NYHA) functional class
17 Not yet recruiting UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure
Conditions: Pre-hypertension;   JNC 7 Stage I Hypertension
Interventions: Drug: Allopurinol;   Drug: Placebo
Outcome Measures: Serum urate level;   Endothelial function as measured by flow mediated dilation (FMD)
18 Recruiting Busulfan and Cyclophosphamide Followed By ALLO BMT
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
Outcome Measures: Disease Free Survival;   Days to Neutrophil Engraftment;   Incidence of Acute Graft-Versus-Host Disease;   Incidence of Chronic Graft-Versus-Host Disease;   Incidence of Treatment-Related Toxicity;   Incidence of Relapse;   Incidence of Engraftment Failure;   Overall Survival
19 Recruiting Study of Cardiovascular Disease and Obstructive Sleep Apnea
Conditions: Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour);   Hypertension
Interventions: Drug: Losartan;   Drug: Allopurinol;   Drug: Placebo
Outcome Measures: Muscle sympathetic nerve activity responses during hypoxia;   Aortic Pulse Wave Velocity;   Cerebral Blood Flow;   Forearm Blood Flow;   Minute ventilation at rest and during hypoxia;   Aortic Augmentation Index;   % Vasodilation;   Apnea Threshold;   Apnea-Hypopnea Index;   % Time Spent Below 90% Oxygen Saturation;   Mean Blood Pressure
20 Not yet recruiting Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack
Condition: Ischaemic Stroke
Interventions: Drug: Allopurinol;   Drug: Placebo
Outcome Measures: White matter hyper-intensities (WMH) progression rate over 2 years, defined using the Rotterdam Progression Score;   change in mean day-time systolic BP at 1 month;   change in mean day-time diastolic BP at 1 month;   Schmidt's Progression Score;   Fazekas score;   Scheltens scale score;   New brain infarction on MRI;   Rotterdam Progression Score with those who die / become too frail to undergo MRI being assigned the highest score;   Montreal Cognitive Assessment (MoCA) score;   Incident dementia;   change in mean day-time systolic BP at 2 years;   change in mean day-time diastolic BP at 2 years;   blood pressure variability;   Quality of life (EQ-5D, Stroke Specific Quality of Life Scale (SS-QOL));   Recurrent stroke;   Recurrent myocardial infarction (MI), stroke or cardiac death;   Mortality;   Incident atrial fibrillation;   Clinic blood pressure

These studies may lead to new treatments and are adding insight into Zyloprim etiology and treatment.

A major focus of Zyloprim research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Zyloprim